Moscow. November 11, 2020. Sputnik V, Russia’s experimental COVID-19 vaccine para manuh ke coronavirus bemar para 92% dak pachaboli pareh, interim trial result hesab te Russian Direct Investment Fund (RDIF) para Wednesday din janai thishe. Duniyaa te Russia toh first country ase, tai khan August moina te COVID-19 vaccine register korishe. Gamaleya Research Institute aro Russian defence ministry para bona vaccine toh etai samai Moscow te late-stage trial jaiase. Etu interim results toh first te 16,000 trial manuh khan logot tuita(2) vaccine thishe, koikena country’s sovereign wealth fund para koishe. Gamaleya Institute para bona Phase III trial laga shot toh etai Moscow pithor te 29 clinics te kam jaiase aro etu samai sob melaikena 40,000 volunteers khan thakibo, etu laga quarter khan toh placebo shot pabo, khobor toh Reuters para koishe. COVID-19 bemar thuriboli toh kaun manuh khan placebo loikena thaka logot Sputnik V loikena thaka toh 92% komti ase, koikena RDIF para Reuters kowa janaishe. “ami khan data hesab te thikai ase aro ami khan logot besi bhal vaccine ase, RDIF laga head Kirill Dmitriev para koishe. Monday din vaccine bona Pfizer Inc aro BioNTech para koishe ke, tai khan laga tawai toh 90% bhal ase kowa beche, Russia para etu khobor junai deya ase Pfizer aro BioNTech laga vaccine te messenger RNA (mRNA) technology choikena immune response deya koishe. Sputnik V vaccine para tuita shots soru koriboli bonaishe aro etu 21 din alag-alag te thikena common cold: human adenoviruses Ad5 aro Ad26 olai koishe.
Add Comment